Regular blood testing reveals metabolic health, inflammation levels, and disease risk. Here are the key markers longevity experts monitor.
In modern medicine, we've developed an extraordinary capability that most people barely use: the ability to peer inside our bodies through blood work and gain objective insight into our health long before symptoms emerge. This is the power of biomarkers. Unlike subjective measures of wellness or the absence of diagnosed disease, biomarkers provide quantifiable, measurable indicators of what's actually happening in your cells, tissues, and organs. They are early warning systems that can reveal metabolic imbalances, inflammatory patterns, and disease trajectories years before they would manifest as clinical illness. For anyone serious about extending not just lifespan but healthspan—the years you actually feel good and function well—tracking the right biomarkers is essential.
The fundamental principle behind biomarker tracking is simple but profound: what gets measured gets managed. You cannot optimize what you don't measure. A person might feel perfectly healthy while their blood sugar creeps upward, their lipid particles become increasingly atherogenic, or their inflammatory markers rise silently in the background. By the time symptoms arrive, damage has often already accumulated. Conversely, someone who feels fine might discover through testing that their metabolic health is excellent, their inflammation is minimal, and their future disease risk is low. This knowledge is empowering and actionable in ways that intuition alone can never be.
Blood biomarkers serve as intermediate endpoints that correlate with actual health outcomes. While we can't measure lifespan directly in living patients, we can measure the biological systems that predict it. A landmark study from Cleveland Clinic showed that cardiorespiratory fitness is one of the strongest predictors of mortality, but similar relationships exist for the numbers in your blood. An elevated fasting insulin indicates metabolic dysfunction years before glucose levels become diabetic. High apolipoprotein B levels signal cardiovascular risk long before a heart attack occurs. A rising C-reactive protein points to underlying inflammation that precedes cancer, dementia, and cardiovascular disease. This is why the world's leading longevity practitioners obsessively track blood biomarkers. They understand that blood work is a window into your biology that no amount of feeling fine can provide.
The traditional medical model focuses on disease diagnosis. A doctor checks your glucose and only becomes concerned if it exceeds 126 mg/dL (the diagnostic threshold for diabetes). Your cholesterol might be 220, which is technically "high," but unless you've already had a heart attack, you might not be treated aggressively. Your C-reactive protein comes back normal by laboratory standards, so your inflammation is deemed inconsequential. But this approach misses the point entirely. Most people develop chronic diseases gradually, through progressive metabolic dysfunction that exists in the pre-clinical space—the years when biomarkers are heading in the wrong direction but haven't yet triggered a diagnosis.
Longevity medicine practitioners adopt a different framework. Rather than asking "Does this person have a disease?" they ask "What is this person's risk of developing major causes of death and disability?" This requires understanding which biomarkers predict adverse outcomes and where on the spectrum health actually lies, not where disease begins. A fasting glucose of 95 mg/dL doesn't trigger a diabetes diagnosis, but research shows it predicts increased cardiovascular risk and is associated with subtle cognitive decline. An HbA1c of 5.6 percent—technically in the normal range—indicates that your average blood sugar is trending upward and your risk of developing diabetes in the next five to ten years is substantially elevated compared to someone with an HbA1c of 5.1 percent. These distinctions matter enormously for someone trying to optimize their long-term health.
The lipid panel illustrates this principle perfectly. For decades, the medical establishment focused on LDL cholesterol as the primary cardiovascular risk factor. Statin therapy aimed to get your LDL "low enough," with target levels declining over time as studies accumulated. But LDL is actually a particle count distribution—there are large, buoyant LDL particles and small, dense LDL particles, and they carry vastly different cardiovascular risk. A person with a high LDL cholesterol number composed mostly of large particles might have lower risk than someone with a lower LDL number composed of numerous small particles. The field eventually embraced apolipoprotein B (ApoB) as the superior marker because it measures the actual number of atherogenic particles regardless of their size.
Peter Attia, one of the most evidence-focused physicians in longevity medicine, describes ApoB as one of the most important numbers in your blood for predicting cardiovascular disease risk. Where conventional medicine might accept an ApoB of 130 mg/dL as normal, longevity practitioners target below 80 mg/dL for optimal protection. This isn't arbitrary. The difference reflects the understanding that cardiovascular disease exists on a continuum of risk, and that the lowest risk occurs at the lowest ApoB levels. Lipoprotein(a), another component of the lipid panel that's largely genetic and doesn't respond to lifestyle interventions, provides a window into familial cardiovascular risk. Testing it once gives you a lifetime risk estimate; if it's high, you know you need aggressive management of other modifiable factors.
Your glucose metabolism is another crucial window into aging. Fasting glucose, measured after eight hours without food, reveals how well your body maintains steady blood sugar at rest. A fasting glucose of 100 mg/dL or higher is officially "pre-diabetic," but the truth is that elevated fasting glucose at any level above roughly 85-90 mg/dL indicates some degree of metabolic dysfunction. The hormone insulin, measured simultaneously during the fasting state and used to calculate the HOMA-IR (Homeostatic Model Assessment for Insulin Resistance), shows whether your cells are responding normally to this signal or whether you've developed insulin resistance. Insulin resistance is perhaps the most common metabolic dysfunction in modern humans and is causally involved in virtually every chronic disease of aging.
HbA1c, the three-month average of your blood glucose, provides crucial longer-term perspective. Because blood glucose fluctuates constantly throughout the day in response to meals, stress, sleep, and hormones, a single fasting reading captures only a moment. HbA1c—formed by glucose binding to hemoglobin in red blood cells—stays elevated for the lifespan of those cells, roughly three months. It thus represents your typical glucose control over that period. A reading of 5.7 percent is officially pre-diabetic, but optimal for longevity is typically below 5.5 percent. This tells you that your average blood sugar is well-controlled, you're not driving excessive glycation of proteins (a process that damages tissues and accelerates aging), and your risk of metabolic disease is low.
Inflammation is both a cause and consequence of aging. The chronic, low-grade inflammatory state that develops in many people as they age—sometimes called "inflammaging"—contributes to virtually every major chronic disease. High-sensitivity C-reactive protein (hs-CRP) measures inflammation with exquisite sensitivity, detecting levels a hundred times lower than the traditional CRP test. An hs-CRP above 3 mg/L is associated with elevated cardiovascular risk. Many longevity practitioners aim for below 1 mg/L. Homocysteine is another inflammatory marker that's often overlooked in standard medical practice. It's an amino acid byproduct that, at elevated levels, damages arterial walls, promotes thrombosis, and is associated with cognitive decline and cardiovascular disease. Optimal levels are below 10 micromoles per liter, and many aim for below 8.
Organ function markers reveal how well your liver and kidneys are handling the daily work of metabolism and detoxification. Liver enzymes like ALT and AST should be low—elevations suggest fatty liver disease, which is extraordinarily common and usually silent. GGT (gamma-glutamyl transferase) is particularly sensitive to fatty liver and also predicts mortality independent of other factors. Kidney function, assessed through creatinine and the eGFR (estimated glomerular filtration rate) derived from it, shows how well your kidneys filter waste. Cystatin C is an emerging marker that may be more accurate than creatinine for estimating kidney function, particularly in elderly individuals.
Beyond these foundational markers lie advanced biomarkers that reveal deeper aspects of your biology. Hormonal health changes profoundly with age, and hormone levels predict both healthspan and lifespan. Testosterone in men and estrogen and progesterone in women decline gradually over decades, and optimization of these hormones—when appropriate—correlates with better health. DHEA-S, the adrenal hormone that gradually declines with age, shows some association with longevity. The thyroid panel, including TSH, free T3, and free T4, reveals metabolic rate and energy production. Insulin-like growth factor 1 (IGF-1) reflects growth hormone status and shows complex relationships with aging and disease.
Nutrient status also deserves attention. Vitamin D is perhaps the most important nutrient to test because deficiency is remarkably common—affecting a large percentage of the population—and is associated with increased all-cause mortality, immune dysfunction, bone loss, and increased cancer and cardiovascular disease risk. Levels below 20 ng/mL are deficient; below 30 is insufficient. Optimal levels for longevity are typically 40-60 ng/mL. Vitamin B12 is crucial for nerve health and energy metabolism; deficiency causes neurological damage even before obvious blood abnormalities appear. Ferritin stores iron and can be a marker of both iron deficiency and iron excess; either extreme is problematic. RBC magnesium is a poorly measured but important nutrient—most blood magnesium tests measure serum magnesium, which is tightly regulated and doesn't reflect total body stores, while RBC magnesium is more accurate. The omega-3 index, measuring the percentage of EPA and DHA in your red blood cells, has emerged as one of the most important predictors of health and mortality, with optimal levels above 8 percent.
What makes biomarker tracking genuinely powerful is understanding that "normal" and "optimal" are different things. Laboratory reference ranges are typically based on population averages. Normal ranges for glucose are based on what's common in a population where metabolic disease is rampant. Optimal ranges for longevity are based on the levels associated with disease prevention and extended healthspan. This gap between normal and optimal is where the actual health gains exist. Someone with a fasting glucose of 100 mg/dL is technically still normal by the lab's reference range, but they're already experiencing metabolic dysfunction compared to someone at 85 mg/dL.
The frequency of testing matters for practical implementation. Most people benefit from comprehensive baseline testing to establish their starting point and identify any areas needing intervention. After that, annual testing is generally reasonable for people in good health who've implemented healthy lifestyle measures. For those optimizing performance or addressing specific issues, quarterly or even monthly testing can make sense to track the impact of interventions. Some tests, like Lp(a), only need to be done once because the result doesn't change meaningfully over time—it's genetic. The cost of testing has plummeted with direct-to-consumer labs, making comprehensive panels far more accessible than they were a decade ago.
Beyond traditional blood biomarkers, the concept of biological age assessment has emerged as perhaps the most direct measure of how fast you're aging at the cellular level. Epigenetic clocks represent one of the most exciting developments in aging science. These clocks measure DNA methylation patterns—chemical modifications to DNA that don't change the genetic sequence but regulate which genes are expressed. Steve Horvath, the researcher who pioneered the Horvath Clock, discovered that methylation patterns show a remarkable correlation with chronological age and, more importantly, with health outcomes and mortality risk.
The original Horvath Clock was trained to predict chronological age from methylation patterns, and it does so with extraordinary accuracy. But more interesting are second-generation clocks trained not on age but on health outcomes. PhenoAge was trained to predict mortality and health-related outcomes, incorporating blood biomarker information alongside methylation patterns. GrimAge was specifically trained to predict remaining lifespan. These clocks can reveal whether someone is aging faster or slower than their chronological age would suggest. Someone with a biological age five years younger than their chronological age is on a trajectory toward greater longevity. Someone with biological age five years older is aging more rapidly and likely needs intervention. The exciting part is that these biological ages are modifiable. Implementing longevity interventions—improved sleep, regular exercise, dietary optimization—has been shown to improve biological age scores in some research.
Functional tests complement blood biomarkers by revealing how well your body's systems actually work. VO2 max, measured through cardiopulmonary exercise testing, represents your maximum aerobic capacity and is one of the strongest predictors of all-cause mortality. The Cleveland Clinic study showed that moving from poor fitness to average fitness reduced mortality risk by nearly fifty percent, a benefit comparable to quitting smoking. Yet most people have never had their VO2 max measured. Blood pressure is a simple but powerful functional marker—optimal is below 120/80, and hypertension is both a cause and consequence of aging. Grip strength, measured with a dynamometer, predicts mortality independent of other factors and reflects overall muscular health. Walking speed, measured in a simple timed walk test, is another remarkable predictor of longevity; people who walk slowly have substantially elevated mortality risk compared to brisk walkers.
The practice of tracking biomarker trends over time is where the real power emerges. A single blood test provides a snapshot. Multiple tests over months and years reveal trajectories. Are your glucose and insulin improving after dietary changes? Is your inflammation decreasing as you increase exercise? Is your lipid profile shifting in the right direction as you optimize your diet? The ability to see these changes accumulate provides powerful feedback and motivation. It transforms abstract recommendations like "eat healthier" into concrete, measurable changes in the actual biology that predicts disease risk and longevity.
The emotional and motivational component of this data shouldn't be underestimated. Many people adopt healthier behaviors out of abstract concern for future risk. But that future risk is distant and therefore motivationally weak. When you can look at your actual biomarker improvements—your hs-CRP dropping from 2.8 to 1.5 mg/L, your HbA1c decreasing from 5.8 percent to 5.3 percent, your ApoB falling from 110 to 75 mg/dL—the abstract becomes concrete. You're not just following a health protocol; you're measurably improving the biological markers that predict whether you'll develop heart disease, diabetes, dementia, and cancer.
Getting started with biomarker tracking requires identifying which tests matter most for your individual situation. A comprehensive baseline metabolic panel including glucose, insulin, lipids (including ApoB and Lp(a)), liver and kidney function, and inflammation markers provides the foundation. Adding vitamin D, omega-3 index, and homocysteine rounds out a solid basic assessment. For those with family history of specific conditions or particular risk factors, targeted additional tests make sense. Working with a practitioner familiar with longevity medicine—whether your primary care doctor or a specialized longevity clinic—ensures that testing is appropriate and that the results are interpreted through an optimized health lens rather than a disease diagnosis lens.
The infrastructure for biomarker testing has become remarkably accessible. You no longer need to convince your primary care physician to order every test you want; direct-to-consumer labs allow you to order your own testing in most states. Insurance may or may not cover comprehensive biomarker testing; some employers offer benefits specifically for preventive testing through services like InsideTracker or Cleveland Heart Lab. The investment in testing, typically running one hundred to five hundred dollars per comprehensive panel depending on which tests you select, is small compared to the cost of treating chronic disease and small compared to the value of the data you receive.
What makes this all actionable is translating numbers into interventions. Elevated fasting glucose and insulin point toward dietary changes—reducing refined carbohydrates and added sugars, implementing time-restricted eating, and increasing physical activity all improve insulin sensitivity and glucose control. High ApoB suggests a need for increased plant-based foods, reduced saturated fat, and possibly pharmacotherapy if lifestyle changes prove insufficient. Elevated hs-CRP and homocysteine suggest a need for increased vegetable intake, regular exercise, omega-3 supplementation, and possibly B-vitamin support. Low vitamin D requires supplementation to reach optimal levels. Low omega-3 index suggests increased fish consumption or supplementation.
The journey toward longevity through biomarker optimization is not about achieving perfection on every single test. It's about establishing baselines, identifying the areas of greatest leverage for your individual biology, implementing evidence-based interventions, and then measuring your response. Some people are highly responsive to dietary changes; others see greater benefits from exercise. Some have genetic predispositions to high Lp(a) that lifestyle changes can't fully address, requiring pharmacotherapy. The beauty of the biomarker approach is that it allows for individualization. You're not following a one-size-fits-all protocol; you're following a protocol informed by your actual biology.
In the emerging science of longevity, few tools are as powerful and accessible as regular biomarker testing. Blood is a window into your biology that's far more honest than how you feel or what you look like. Your blood tells the truth about your metabolic health, your inflammatory status, your organ function, and your trajectory. Armed with this information and the willingness to act on it, you hold one of the most powerful tools available for extending not just how long you live but how well you live.